|  Post Reply

LONDON, Dec 24 (Reuters) - AstraZeneca said on Tuesday it had voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for treatment of a type of lung cancer.

The drug, DreamProxies.Com datopotamab deruxtecan (Dato-DXd), which has been jointly developed with Japan's Daiichi Sankyo, was granted a breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) earlier this month for treatment of the same type of lung cancer when other treatments have failed.

(Reporting by Maggie Fick; Editing by Kirsten Donovan)

Add comment